Open Clinical Trials

Feline, fibrosarcoma, interleukin-2, ALVAC-IL2, PHN 624

Purpose: To assess the ability of Merial’s Feline Interleukin-2 immunomodulator, Live Canarypox Vector to increase the time to tumor recurrence when administered to cats as an adjunct treatment to surgical excision of fibrosarcoma, and to demonstrate safety when used under field conditions in affected cats.

Exclusion Criteria:

Tumors located on the head, tail, or distal limbs

Evidence of metastatic disease

Cats with significant co-morbid illness which, in the opinion of the investigator or sponsor, could compromise response to the treatment, interfere with evaluation of its efficacy, or result in the mortality within one year. This includes but is not limited to renal or hepatic failure, history of congestive heart failure or clinical coagulopathy.

Cats having received previous immunotherapy

Cats receiving concurrent chemotherapy ( including corticosteroids) or radiation therapy. Casts must be off of all such therapy for 3 weeks prior to study enrollment

Concurrent medications deemed incongruent with this study. All pre-existing necessary medications should be recorded as concomitant medications

Cats in the care of owners/designee living at a distance from the treatment center that in the opinion of the investigator will make compliance with follow-up incompatible with reasonable travel arrangements

 

B-cell Lymphoma Vaccine, DNA

Purpose: Evaluation of the efficacy and safety of a vaccine for the extension of post-chemotherapeutic remission times in dogs diagnosed with large B-cell lymphoma. Remission status established 2-4 weeks following of CHOP therapy.

Exclusion Criteria:

Dogs that exhibit CNS involvement prior to CHOP- based therapy

Dogs with medical illness other than large B-cell lymphoma that, in the opinion of the oncologist could compromise response to the vaccine or interfere with evaluation of  its efficacy

Dogs having received previous immunotherapy

Dogs having received long-acting, systemic steroids within 30 days prior to enrollment in the study

Dogs in the care of owners/designee living at a distance from the treatment center that will make compliance with the follow-up incompatible with reasonable travel arrangements.

Canine Osteosarcoma Vaccine, Live Listeria Vector

Inclusion Criteria:

Written owner informed consent

Client-owned dog- 1 year of age

Body weight: 2kg

Histopathologic diagnosis of osteosarcoma

Amputation of the affected limb complete and followed by 4-6 doses of carboplatin

Performance score of 0 to 1 (0=normal activity; 1=restricted activity, decreased activity from pre-disease status, 2=compromised ambulatory only for vital activities, consistently defecates and urinates in acceptable areas.

Exclusion Criteria:

Clinically relevant abnormalities on CBC/CS/UA

Evidence of pulmonary metastases on 3-view thoracic radiographs

Prior immunotherapy

Any uncontrolled medical condition ( including other concurrent malignancy) that may be disruptive to the intent and objectives of the study

Dog is pregnant or likely to become pregnant

Dog is participating in another study

Dog may not be available for the entire study duration